VENLAFAXINA AUROBINDO 37.5mg prolonged release capsules medication leaflet

N06AX16 venlafaxine • Nervous system | Antidepressants | Other antidepressants

Venlafaxine is a medication used to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. It belongs to the class of serotonin-norepinephrine reuptake inhibitors (SNRIs), working by increasing the levels of these neurotransmitters in the brain, which helps regulate mood and reduce anxiety symptoms.

Venlafaxine is usually taken once daily as extended-release tablets and can be taken with or without food. The dosage is gradually adjusted based on the patient's response and tolerance.

Common side effects include nausea, dizziness, dry mouth, insomnia, excessive sweating, and loss of appetite. In some cases, it may cause an increase in blood pressure, so regular monitoring is necessary.

It is important not to stop venlafaxine treatment abruptly, as this can lead to withdrawal symptoms such as irritability, dizziness, or sleep disturbances. Patients should strictly follow their doctor's recommendations and discuss any side effects or concerns.

General data about VENLAFAXINA AUROBINDO 37.5mg

Substance: venlafaxine

Date of last drug list: 01-03-2020

Commercial code: W66463015

Concentration: 37.5mg

Pharmaceutical form: prolonged release capsules

Quantity: 500

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: APL SWIFT SERVICES (MALTA) LIMITED - MALTA

Holder: AUROBINDO PHARMA ROMANIA SRL - ROMANIA

Number: 12464/2019/15

Shelf life: 3 years

Pharmaceutical forms available for venlafaxine

Concentrations available for venlafaxine

150mg, 25mg, 37.5mg, 50mg, 75mg